Skip to main content
SpringerLink
Log in

Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents

  • Review Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell disorders. The International Prognostic Score System (IPSS) groups MDS in lower-risk (IPSS low and intermediate-1) and higher-risk disease (IPSS intermediate-2 and high). AML transformation is the main concern in higher-risk MDS, while anemia and transfusion dependency represent the major issues for low-risk MDS patients. Improving erythropoiesis, and eliminating fatigue and symptoms, is the main therapeutic goal for low-risk MDS patients. Around 50% of MDS patients present with anemia with an Hb level < 100 g/L. Severe anemia increases the negative effects of comorbidities, such as heart and lung failure. Erythropoiesis-stimulating agents (ESAs), with or without granulocyte colony-stimulating factor, induce erythroid response rates in 40–50% of lower-risk anemic MDS patients. The median response duration of 24 months. Apoptosis of erythroid cells is inhibited by ESAs leading to erythrocyte production. Our paper considers the state of the art of treatment of anemia in low-risk MDS patients and the treatment options in MDS resistant or refractory to ESAs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: contemporary review and how we treat. Am J Hematol. 2016;91(1):76–89.

    Article  CAS  PubMed  Google Scholar 

  2. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361(19):1872–85.

    Article  CAS  PubMed  Google Scholar 

  3. Gidaro A, Deliliers GL, Gallipoli P, Arquati M, Wu MA, Castelli R. Laboratory and clinical risk assessment to treat myelodysplatic syndromes. Clin Chem Lab Med. 2016;54(9):1411–26.

    CAS  PubMed  Google Scholar 

  4. Cazzola M, Malcovati L. Myelodysplastic syndromes—coping with ineffective hematopoiesis. N Engl J Med. 2005;352(6):536–8.

    Article  CAS  PubMed  Google Scholar 

  5. Hellström-Lindberg E, van de Loosdrecht A. Erythropoiesis stimulating agents and other growth factors in low-risk MDS. Best Pract Res Clin Haematol. 2013;26(4):401–10.

    Article  PubMed  Google Scholar 

  6. Pfeilstöcker M, Karlic H, Nösslinger T, et al. Myelodysplastic syndromes, aging, and age: correlations, common mechanisms, and clinical implications. Leuk Lymphoma. 2007;48(10):1900–9.

    Article  PubMed  Google Scholar 

  7. Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011;96(3):441–9.

    Article  PubMed  Google Scholar 

  8. de Swart L, Smith A, Johnston TW, et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol. 2015;170(3):372–83.

    Article  PubMed  Google Scholar 

  9. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503–10.

    Article  PubMed  Google Scholar 

  10. Pfeilstöcker M, Tuechler H, Sanz G, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128:902–10.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hellström-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99(2):344–51.

    Article  PubMed  Google Scholar 

  12. Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood. 2004;104(2):321–7.

    Article  CAS  PubMed  Google Scholar 

  13. Jädersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26(21):3607–13.

    Article  PubMed  Google Scholar 

  14. Park S, Kelaidi C, Sapena R, et al. Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. Leuk Res. 2010;34(11):1430–6.

    Article  PubMed  Google Scholar 

  15. Cazzola M, Barosi G, Berzuini C, et al. Quantitative evaluation of erythropoietic activity in dysmyelopoietic syndromes. Br J Haematol. 1982;50(1):55–62.

    Article  CAS  PubMed  Google Scholar 

  16. Bouscary D, De Vos J, Guesnu M, et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 1997;11(6):839–45.

    Article  CAS  PubMed  Google Scholar 

  17. Koike M, Ishiyama T, Tomoyasu S, Tsuruoka N. Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia. Leuk Res. 1995;19(9):639–44.

    Article  CAS  PubMed  Google Scholar 

  18. Shetty V, Mundle S, Alvi S, et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res. 1996;20(11–12):891–900.

    Article  CAS  PubMed  Google Scholar 

  19. Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol. 2007;35(11):1739–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Epling-Burnette PK, Painter JS, Rollison DE, et al. Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia. 2007;21(4):659–67.

    Article  CAS  PubMed  Google Scholar 

  21. Baumann I, Scheid C, Koref MS, Swindell R, Stern P, Testa NG. Autologous lymphocytes inhibit hemopoiesis in long-term culture in patients with myelodysplastic syndrome. Exp Hematol. 2002;30(12):1405–11.

    Article  PubMed  Google Scholar 

  22. Castelli R, Deliliers GL, Colombo R, Moreo G, Gallipoli P, Pantaleo G. Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function. Ann Hematol. 2014;93(9):1523–9.

    Article  CAS  PubMed  Google Scholar 

  23. Castelli R, Sciara S, Deliliers G, Pantaleo GL. Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot study. Ann Hematol. 2017;96(5):779–86.

    Article  CAS  PubMed  Google Scholar 

  24. Rosti G, Petrini M, Bosi A, et al. Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study. Ther Adv Med Oncol. 2017;9(1):22–32.

    Article  CAS  PubMed  Google Scholar 

  25. Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res. 2007;31(Suppl 3):S2–6.

    Article  CAS  PubMed  Google Scholar 

  26. Castelli R, Schiavon R, Deliliers GL. The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes. Med Oncol. 2018;35(3):33.

    Article  PubMed  Google Scholar 

  27. Bennett JM. MDS Foundation’s Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83(11):858–61.

    Article  PubMed  Google Scholar 

  28. Cazzola M, Malcovati L. Prognostic classification and risk assessment in myelodysplastic syndromes. Hematol Oncol Clin N Am. 2010;24(2):459–68.

    Article  Google Scholar 

  29. Sanz C, Nomdedeu M, Belkaid M, Martinez I, Nomdedeu B, Pereira A. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion. 2013;53(4):710–5.

    Article  CAS  PubMed  Google Scholar 

  30. Leisch M, Weiss L, Lindlbauer N, et al. Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine—a retrospective single center experience. Leuk Res. 2017;59:12–9.

    Article  CAS  PubMed  Google Scholar 

  31. Fenaux P, Haase D, Sanz GF, Santini V, Buske C, ESMO Guidelines Working Group. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2014;25(Suppl 3):iii57-69.

    Google Scholar 

  32. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557–66.

    Article  CAS  PubMed  Google Scholar 

  33. Oliva EN, Ronco F, Marino A, Alati C, Praticò G, Nobile F. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion. 2010;50(7):1568–70.

    Article  PubMed  Google Scholar 

  34. Badawi MA, Vickars LM, Chase JM, Leitch HA. Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome. Adv Hematol. 2010;2010:164045.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Vinholt PJ, Alnor A, Nybo M, Hvas A-M. Prediction of bleeding and prophylactic platelet transfusions in cancer patients with thrombocytopenia. Platelets. 2016;27:1–8.

    Article  Google Scholar 

  36. Yu H-C, Zhao H-L, Wu Z-K, Zhang J-W. Eos negatively regulates human γ-globin gene transcription during erythroid differentiation. PLoS ONE. 2011;6(7):e22907.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Tehranchi R, Fadeel B, Forsblom A-M, et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood. 2003;101(3):1080–6.

    Article  CAS  PubMed  Google Scholar 

  38. Duong VH, Baer MR, Hendrick F, et al. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response. Leuk Res. 2015;39(6):586–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Castelli R, Bergamaschini L, Schiavon R, Lambertenghi-Deliliers G. Personalized treatment strategies for elderly patients with myelodysplastic syndromes. Expert Rev Hematol. 2017;10:1–10.

    Article  Google Scholar 

  40. Spiriti MAA, Latagliata R, Niscola P, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol. 2005;84(3):167–76.

    Article  CAS  PubMed  Google Scholar 

  41. Park S, Fenaux P, Greenberg P, et al. Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis. Br J Haematol. 2016;174(5):730–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009;114(12):2393–400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594–603.

    Article  PubMed  Google Scholar 

  44. Oliva EN, Finelli C, Santini V, et al. Quality of life and physicians’ perception in myelodysplastic syndromes. Am J Blood Res. 2012;2(2):136–47.

    PubMed  PubMed Central  Google Scholar 

  45. Gabrilove J, Paquette R, Lyons RM, et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol. 2008;142(3):379–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Musto P, Villani O, Martorelli MC, et al. Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes. Leuk Res. 2010;34(8):981–5.

    Article  CAS  PubMed  Google Scholar 

  47. Kelaidi C, Beyne-Rauzy O, Braun T, et al. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol. 2013;92(5):621–31.

    Article  CAS  PubMed  Google Scholar 

  48. Balleari E, Clavio M, Arboscello E, et al. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes. Leuk Res. 2011;35(11):1472–6.

    Article  CAS  PubMed  Google Scholar 

  49. Spinelli E, Caporale R, Buchi F, et al. Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. Clin Cancer Res. 2012;18(11):3079–89.

    Article  CAS  PubMed  Google Scholar 

  50. Jädersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellström-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood. 2005;106(3):803–11.

    Article  PubMed  Google Scholar 

  51. Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122(17):2943–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Almeida A, Fenaux P, List AF, Raza A, Platzbecker U, Santini V. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leuk Res. 2017;52:50–7.

    Article  CAS  PubMed  Google Scholar 

  53. Yazji S, Giles FJ, Tsimberidou A-M, et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia. 2003;17(11):2101–6.

    Article  CAS  PubMed  Google Scholar 

  54. Broliden PA, Dahl I-M, Hast R, et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica. 2006;91(5):667–70.

    CAS  PubMed  Google Scholar 

  55. Passweg JR, Giagounidis AAN, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/99. J Clin Oncol. 2011;29(3):303–9.

    Article  CAS  PubMed  Google Scholar 

  56. Komrokji RS, Mailloux AW, Chen D-T, et al. A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. Haematologica. 2014;99(7):1176–83.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Fenaux P, Gattermann N, Seymour JF, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol. 2010;149(2):244–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562–9.

    Article  CAS  PubMed  Google Scholar 

  59. Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011;29(18):2521–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Castelli R, Cassin R, Cannavò A, Cugno M. Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013;13(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  61. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549–57.

    Article  CAS  PubMed  Google Scholar 

  62. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456–65.

    Article  CAS  PubMed  Google Scholar 

  63. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765–76.

    Article  CAS  PubMed  Google Scholar 

  64. Le Bras F, Sebert M, Kelaidi C, et al. Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—the GFM experience. Leuk Res. 2011;35(11):1444–8.

    Article  PubMed  Google Scholar 

  65. Toma A, Kosmider O, Chevret S, et al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia. 2016;30(4):897–905.

    Article  CAS  PubMed  Google Scholar 

  66. Sibon D, Cannas G, Baracco F, et al. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. Br J Haematol. 2012;156(5):619–25.

    Article  CAS  PubMed  Google Scholar 

  67. Zeidan AM, Al Ali NH, Padron E, Lancet J, List A, Komrokji RS. Lenalidomide treatment for lower risk nondeletion 5q myelodysplastic syndromes patients yields higher response rates when used before azacitidine. Clin Lymphoma Myeloma Leuk. 2015;15(11):705–10.

    Article  PubMed  Google Scholar 

  68. Park S, Hamel J-F, Toma A, et al. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents. J Clin Oncol. 2017;35(14):1591–7.

    Article  PubMed  Google Scholar 

  69. Mies A, Platzbecker U. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors. Semin Hematol. 2017;54(3):141–6.

    Article  PubMed  Google Scholar 

  70. Platzbecker U, Germing U, Götze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18:1338–47.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco Hospital Milan, University of Milan, Milan, Italy

    Roberto Castelli & Riccardo Schiavon

  2. Hematology and Transfusion Medicine, Department of Oncology and Onco-Hematology, L. Sacco University Hospital, University of Milan, Milan, Italy

    Valentina Rossi

  3. Fondazione Matarelli Milano, Milan, Italy

    Giorgio Lambertenghi Deliliers

Authors
  1. Roberto Castelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riccardo Schiavon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valentina Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giorgio Lambertenghi Deliliers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberto Castelli.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Castelli, R., Schiavon, R., Rossi, V. et al. Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents. Med Oncol 35, 76 (2018). https://doi.org/10.1007/s12032-018-1135-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-018-1135-2

Keywords

Search

Navigation